Journal article

Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 31/2 years duration

CW Ritchie, S Harrigan, M Mastwyk, S Macfarlane, M Cheesman, D Ames



OBJECTIVE: Although the evidence base for the use of antipsychotics in older people with schizophrenia is generally of low quality, it tends to support the use of atypical antipsychotics. Only limited information regarding longer term adherence to these apparently more effective drugs is available. The aim of this study was to determine predictors of adherence to risperidone or olanzapine in patients over 60. METHODS: Patients receiving care from old age psychiatrists for their schizophrenia were randomised to treatment with olanzapine or risperidone and were followed for up to 3(1/2) years. Kaplan-Meier curves were generated to assess the univariate effect of randomisation drug on long-term..

View full abstract

University of Melbourne Researchers


Funding Acknowledgements

This study was funded by an educational grant from Eli Lilly (Australia). The authors acknowledge the support of the following Australian centres: Frankston, St George's, Caulfield and the Austin Hospitals and the Mental Health Research Institute, (Victoria), Rozelle Hospital (New South Wales), Glenside and Parkside Hospitals (South Australia). The authors specifically acknowledge the following investigators and researchers who worked on this project: Prof. Ed Chiu, Dr Kathy Hall, Prof. Daniel O'Connor, Vathy Nagalingum, Janet Opie, Prof. Anne Hassett, Prof. John Snowdon, Dr Graeme Halliday and Prof. Harry Hustig.